The Iron-Overloaded Patient: A Guide to Hereditary Hemochromatosis

Dr Neeraj Manikath , claude.ai

Abstract

Hereditary hemochromatosis (HH) represents one of the most common inherited disorders in populations of Northern European ancestry, yet remains significantly underdiagnosed despite being eminently treatable. This review provides a comprehensive, evidence-based approach to recognizing, diagnosing, and managing iron overload, with emphasis on the genotype-phenotype disconnect that often confounds clinical decision-making. We highlight practical diagnostic algorithms, explore the nuances of penetrance, and underscore the critical importance of cascade family screening.

Keywords: Hereditary hemochromatosis, HFE gene, iron overload, transferrin saturation, C282Y mutation, family screening

Introduction: The "Common Zebra"

"When you hear hoofbeats, think horses, not zebras" remains a cornerstone of medical education. Yet hereditary hemochromatosis defies this adage—it presents as a zebra (rare, exotic disease) while actually being a horse (common genetic condition). With a homozygous C282Y prevalence of approximately 1 in 200-300 individuals of Northern European descent,¹ HH rivals or exceeds the frequency of many conditions we routinely screen for, including phenylketonuria and congenital hypothyroidism.

The tragedy of HH lies not in its rarity but in its delayed recognition. Patients average 8-10 years from symptom onset to diagnosis,² during which irreversible organ damage accumulates. The liver progresses from steatosis to fibrosis to cirrhosis; pancreatic beta-cells succumb to iron toxicity causing "bronze diabetes"; cardiomyocytes degenerate leading to heart failure; and pituitary gonadotrophs fail, resulting in hypogonadism. Yet with early detection and simple phlebotomy therapy, all of this is preventable.

Pearl #1: Think of hemochromatosis as "rust accumulating in the machinery of life"—slow, silent, and devastating if ignored, but completely preventable if caught early.

The HFE Gene: Molecular Genetics Meets Clinical Medicine

The C282Y Mutation: The Primary Culprit

The HFE gene, located on chromosome 6p21.3, encodes a protein that regulates hepcidin production, the master regulator of systemic iron homeostasis.³ The C282Y mutation (a cysteine-to-tyrosine substitution at position 282) disrupts the protein's tertiary structure, preventing its normal interaction with β2-microglobulin and subsequent cell surface expression.⁴ This results in inappropriately low hepcidin levels, leading to:

Increased duodenal iron absorption (2-4× normal)
Enhanced iron release from macrophages
Progressive parenchymal iron deposition

Approximately 80-95% of clinically significant HH cases in Northern Europeans are C282Y homozygotes.⁵ The mutation likely originated from a single founder in a Celtic population 60-70 generations ago, with subsequent selection possibly related to protection against iron deficiency in low-iron diets.⁶

The H63D Mutation: The Modest Modifier

The H63D variant (histidine-to-aspartate at position 63) is considerably more common (allele frequency ~15% in Europeans) but has minimal clinical penetrance.⁷ H63D homozygotes rarely develop clinically significant iron overload. However, compound heterozygotes (C282Y/H63D) represent approximately 5% of HH cases and typically manifest milder disease with later onset than C282Y homozygotes.⁸

Hack #1: When ordering genetic testing, ensure the laboratory tests for both C282Y and H63D mutations. Some laboratories offer "HFE gene panels" that include rarer mutations (S65C), but C282Y and H63D account for >95% of clinical cases.

Other Rare HFE and Non-HFE Hemochromatosis

Several non-HFE forms exist, including juvenile hemochromatosis (HJV, HAMP genes), transferrin receptor 2-related (TFR2), and ferroportin disease (SLC40A1).⁹ These are rare but important to recognize in patients with:

Very early onset (<30 years) severe iron overload
Cardiac predominance (juvenile hemochromatosis)
Family history incompatible with HFE inheritance
Negative C282Y/H63D testing despite clear phenotype

Penetrance is Key: The Genotype-Phenotype Disconnect

The Penetrance Paradox

Here lies the most clinically vexing aspect of HH: most people with the genotype never develop clinically significant disease. Multiple population studies have demonstrated that while 1 in 200-300 Northern Europeans are C282Y homozygotes, only 10-33% develop biochemical iron overload (elevated ferritin), and a mere 1-10% progress to end-organ damage.¹⁰,¹¹

Pearl #2: Possessing the C282Y homozygous genotype is necessary but not sufficient for clinical hemochromatosis. Think of it as having a "loaded genetic gun"—additional factors determine whether it fires.

Modifying Factors Affecting Penetrance

Sex differences: Men develop clinical disease 5-10 times more frequently than women.¹² Menstrual blood loss and pregnancy provide natural phlebotomy, protecting premenopausal women. Post-menopausal women show increasing phenotypic expression.

Dietary iron: Higher heme iron intake (red meat) accelerates accumulation, while dietary factors affecting iron absorption (tannins in tea, phytates, calcium) modulate penetrance.¹³

Alcohol consumption: Acts synergistically with genetic iron loading, both increasing iron absorption and causing independent hepatotoxicity. Even moderate alcohol consumption (>14 drinks/week) significantly increases cirrhosis risk in C282Y homozygotes.¹⁴

Blood loss/donation: Regular blood donors with HH genotype show dramatically reduced clinical penetrance—essentially treating themselves prophylactically.

Genetic modifiers: Polymorphisms in other iron metabolism genes (BMP6, TMPRSS6) may modulate phenotypic expression.¹⁵

Metabolic syndrome: Obesity, insulin resistance, and hepatic steatosis appear to amplify iron-mediated liver injury, potentially explaining increased penetrance in modern populations.¹⁶

Oyster #1: A patient presenting with seemingly mild iron overload who is a regular blood donor may actually have significant HH genotype but therapeutic phlebotomy from donations. Always ask about blood donation history!

Who to Test: Clinical Suspicion and Screening

The Classic Pentad (Rarely Seen Today)

Historical teaching emphasized the classic pentad of:

Bronze skin hyperpigmentation (iron + melanin deposition)
Diabetes mellitus
Hepatomegaly/cirrhosis
Cardiomyopathy
Hypogonadism

Reality check: This presentation is now uncommon in developed countries due to earlier detection. Today's HH patient presents with subtler findings.

The Modern Clinical Presentation: Fatigue and Beyond

Non-specific symptoms (often dismissed):

Chronic fatigue (present in 75% but non-specific)¹⁷
Arthralgia (particularly 2nd and 3rd MCP joints—a highly specific finding)
Impotence and decreased libido
Abdominal pain

Hepatic manifestations:

Asymptomatic transaminase elevation
Hepatomegaly
Unexplained cirrhosis (10-15% at diagnosis)¹⁸
Hepatocellular carcinoma (200× increased risk if cirrhotic)¹⁹

Endocrine abnormalities:

"Bronze diabetes" (25-60% of symptomatic patients)²⁰
Hypothyroidism
Hypogonadotropic hypogonadism

Cardiac complications:

Dilated cardiomyopathy
Restrictive cardiomyopathy
Arrhythmias (particularly atrial fibrillation)

Arthropathy: The "iron hand" of hemochromatosis—chondrocalcinosis with predilection for MCP joints (especially 2nd/3rd), wrists, hips, and knees. Unlike osteoarthritis, HH arthropathy may occur in young patients and doesn't fully reverse with iron depletion.²¹

Pearl #3: The "MCP sign"—tenderness, swelling, or early osteoarthritis of the 2nd and 3rd metacarpophalangeal joints in a patient with unexplained fatigue should immediately trigger HH screening. This is one of the most specific physical findings.

High-Yield Testing Scenarios

Always screen for HH in these situations:

Unexplained liver disease (elevated transaminases, hepatomegaly, cirrhosis)
Type 2 diabetes + elevated transaminases
Cardiomyopathy in patients <50 years
Arthropathy affecting MCP joints
Hypogonadism with elevated ferritin
First-degree relatives of confirmed HH patients
Persistently elevated serum iron or ferritin on routine labs
Northern European ancestry with chronic fatigue

Hack #2: In young patients with "idiopathic" dilated cardiomyopathy, always check iron studies before assuming viral or alcoholic etiology. Cardiac iron overload is reversible if caught early, but cardiac transplant becomes necessary if diagnosis is delayed.

The Diagnostic Algorithm: A Step-by-Step Approach

Step 1: Initial Screening with Transferrin Saturation and Ferritin

Transferrin saturation (TSAT) is the single best screening test for HH.²² Calculate as: (Serum Iron ÷ Total Iron Binding Capacity) × 100

Normal: <45% (men and women)
Suggestive of HH: ≥45% on fasting specimen
Highly suggestive: ≥60% (men), ≥50% (women)

Serum ferritin reflects total body iron stores but lacks specificity:

Normal: 30-300 ng/mL (men), 15-200 ng/mL (women)
Elevated in HH: >300 ng/mL (men), >200 ng/mL (women)
Severe iron overload: >1000 ng/mL

Critical caveat: Ferritin is an acute-phase reactant. Elevation occurs with:

Inflammation (infection, autoimmune disease)
Malignancy
Metabolic syndrome/NASH
Alcohol use
Hepatocellular injury

Pearl #4: Always order fasting morning TSAT and ferritin together. Isolated ferritin elevation without elevated TSAT suggests secondary causes (inflammation, malignancy) rather than primary iron overload. TSAT ≥45% + ferritin elevation = proceed to genetic testing.

Step 2: HFE Genetic Testing

When screening labs suggest HH (TSAT ≥45%), proceed directly to HFE gene mutation analysis:

Interpretation:

C282Y/C282Y (homozygous): Confirms HH diagnosis
C282Y/H63D (compound heterozygote): Mild HH possible; assess clinical iron overload
C282Y/wild-type (heterozygote): Not HH; investigate other causes
H63D/H63D (homozygous): Rarely causes significant overload
Wild-type/wild-type: Not HFE-related; consider non-HFE hemochromatosis or secondary causes

Oyster #2: A patient who is C282Y heterozygous with significant iron overload deserves thorough investigation. Look for concurrent liver disease (alcohol, NASH, viral hepatitis), hematologic disorders (myelodysplasia, chronic hemolysis), or rare non-HFE hemochromatosis genes.

Step 3: Assessing Disease Severity and End-Organ Damage

Once HH is genetically confirmed with evidence of iron overload, assess for complications:

Hepatic assessment:

Liver enzymes (AST, ALT, alkaline phosphatase)
Liver synthetic function (albumin, INR, bilirubin)
Liver fibrosis assessment:
- Non-invasive: FIB-4 score, APRI, transient elastography (FibroScan)
- Liver biopsy indications: Ferritin >1000 ng/mL + elevated transaminases or clinical suspicion for cirrhosis²³
- Hepatic iron quantification (rarely needed with genetic confirmation)

Endocrine screening:

Fasting glucose, HbA1c (screen for diabetes)
TSH, free T4 (thyroid function)
Morning testosterone, LH, FSH (hypogonadism in men)

Cardiac evaluation:

ECG (conduction abnormalities, arrhythmias)
Echocardiogram if cardiac symptoms or ferritin >1000 ng/mL
Consider cardiac MRI T2* for cardiac iron quantification in severe cases²⁴

Joint assessment:

Plain radiographs of symptomatic joints (look for chondrocalcinosis)
MCP joint X-rays if hand arthropathy suspected

Hack #3: In C282Y homozygotes with ferritin <1000 ng/mL, normal transaminases, and no hepatomegaly, advanced fibrosis is extremely unlikely. These patients can proceed directly to phlebotomy without liver biopsy. This "rule of thumb" saves patients from unnecessary invasive procedures.²⁵

Step 4: Quantifying Iron Burden

Quantitative phlebotomy provides the most accurate assessment of total body iron excess. Each 500 mL unit of blood removes approximately 200-250 mg of iron. Patients with HH typically require 20-50 units to achieve iron depletion (normal ferritin).²⁶

Calculate total excess iron: Excess iron (g) = (Number of phlebotomy units) × 0.225 g iron/unit

Treatment: Therapeutic Phlebotomy and Beyond

Induction Phase: Achieving Iron Depletion

Protocol:

Remove 500 mL whole blood weekly (or 450 mL for smaller patients)
Monitor ferritin monthly initially, then every 2-3 months
Target: Ferritin 50-100 ng/mL (not <50, to avoid iron deficiency)
Duration: Typically 6-24 months depending on initial iron burden

Monitoring during induction:

Pre-phlebotomy hemoglobin (hold if Hb <11 g/dL)
Ferritin every 1-3 months
Once ferritin approaches 100 ng/mL, check TSAT and ferritin before each phlebotomy

Pearl #5: Patients often report dramatic improvement in fatigue within 3-6 months of starting phlebotomy, well before complete iron depletion. This symptomatic improvement provides powerful motivation for adherence.

Maintenance Phase: Lifelong Management

After achieving target ferritin, transition to maintenance phlebotomy:

Frequency varies: Every 2-6 months typically
Individualize based on rate of reaccumulation (check ferritin 3 months after last induction phlebotomy)
Continue indefinitely to maintain ferritin 50-100 ng/mL

Alternative: Blood donation: Motivated patients who meet donor criteria can maintain iron depletion through regular blood donation programs—achieving therapeutic benefit while altruistically helping others.²⁷

Hack #4: Partner with local blood banks. Many accept HH patients as regular donors once diagnosed and initially depleted. This converts a medical treatment into a socially beneficial activity, improving adherence and reducing healthcare costs.

Dietary Modifications: Helpful but Secondary

Reasonable advice:

Moderate red meat consumption (heme iron)
Avoid iron-fortified foods and supplements
Avoid vitamin C supplements with meals (enhances iron absorption)
Limit alcohol (synergistic hepatotoxicity)

Important caveat: Dietary modification alone cannot prevent iron overload in HH. Phlebotomy remains the cornerstone of therapy.

Oyster #3: Patients often obsess over dietary restrictions, feeling they've "failed" if they eat red meat. Emphasize that phlebotomy is far more important than dietary perfection. Removing 500 mL blood eliminates more iron than months of dietary restriction.

Chelation Therapy: Limited Role

Iron chelators (deferoxamine, deferasirox) are reserved for:

Patients who cannot tolerate phlebotomy (severe anemia, cardiac disease)
Transfusion-dependent iron overload
Non-HFE hemochromatosis with specific features

Chelation is inferior to phlebotomy in HH: less effective, more expensive, significant side effects.²⁸

Family Screening: Simple, Life-Saving, Underutilized

The Compelling Case for Cascade Screening

Hereditary hemochromatosis follows autosomal recessive inheritance. First-degree relatives of C282Y homozygotes have:

25% chance of being homozygous (C282Y/C282Y)
50% chance of being heterozygous carriers
25% chance of being unaffected

Cost-effectiveness data overwhelmingly support family screening:

Identifying asymptomatic homozygotes before organ damage occurs
Preventing cirrhosis, diabetes, cardiomyopathy with simple phlebotomy
Extremely favorable cost-per-QALY ratio (<$5000/QALY gained)²⁹

Pearl #6: When you diagnose one HH patient, you have the opportunity to prevent disease in multiple family members. Family screening is arguably more important than treating the index case, who often already has irreversible complications.

Recommended Family Screening Protocol

For first-degree relatives (siblings, children, parents) of C282Y homozygotes:

Genetic testing PLUS phenotypic testing:
- HFE gene analysis (C282Y, H63D)
- Fasting transferrin saturation and ferritin

Interpretation and follow-up:

C282Y homozygotes with normal iron studies: Annual ferritin and TSAT monitoring; institute phlebotomy if evidence of accumulation
C282Y homozygotes with iron overload: Begin therapeutic phlebotomy immediately
C282Y heterozygotes: Reassurance; no routine monitoring needed (but recheck if develop suggestive symptoms)
Compound heterozygotes (C282Y/H63D): Monitor ferritin/TSAT every 2-3 years; treat if clinically significant overload develops

For children of affected individuals:

If both parents are affected or carriers: Test children in late teens/early twenties (before significant accumulation but after establishing independent healthcare)
If only one parent is C282Y homozygote and other partner's status unknown: Test partner first; if partner is carrier, test children

Hack #5: At diagnosis, give patients a "family screening packet" with a letter explaining HH genetics and recommending that first-degree relatives get tested. Include information about insurance coverage and emphasize that early detection prevents complications. This tangible resource significantly improves screening rates.³⁰

Barriers to Family Screening (and How to Overcome Them)

Common barriers:

Family communication difficulties
Concerns about genetic discrimination (largely addressed by GINA legislation in US)
Lack of symptoms in relatives leading to low motivation
Insurance/cost concerns

Strategies:

Normalize genetic testing as preventive medicine
Provide written materials for patients to share
Emphasize treatability and prevention
Offer family counseling for complex family dynamics
Connect with patient advocacy organizations (Iron Disorders Institute, American Hemochromatosis Society)

Special Populations and Scenarios

Women and Hemochromatosis

Premenopausal women with C282Y homozygosity typically show delayed and milder phenotype due to menstrual iron losses. However, post-menopausally, women progressively accumulate iron and require monitoring.

Pregnancy considerations:

Iron demands of pregnancy naturally depletes maternal stores
HH women rarely need phlebotomy during pregnancy
Screen ferritin postpartum; resume phlebotomy if elevated

Patients with Concurrent Liver Disease

The "double hit" of HH plus another liver insult (alcohol, viral hepatitis, NASH) markedly accelerates fibrosis progression.³¹ These patients require:

Aggressive iron depletion
Treatment of concurrent liver disease
Close monitoring for cirrhosis and HCC
Strong alcohol abstinence counseling

Cirrhotic Patients: Special Considerations

Once cirrhosis develops:

Iron removal still beneficial for reducing HCC risk
Phlebotomy poorly tolerated (anemia common)
Hepatocellular carcinoma screening mandatory (abdominal ultrasound + AFP every 6 months)³²
Consider liver transplantation evaluation if decompensated

Oyster #4: Post-transplant, the new liver does not carry the HFE mutation if the donor was wild-type. However, patients may still reaccumulate iron from transfusions or persistent increased gut absorption, requiring continued monitoring.

Prognosis: The Power of Early Detection

Life Expectancy with Early Treatment

Asymptomatic C282Y homozygotes treated before cirrhosis develops have NORMAL life expectancy.³³ This bears repeating: appropriate screening and early treatment completely prevent HH-related morbidity and mortality.

The Cirrhosis Threshold

Once cirrhosis develops, prognosis changes dramatically:

Hepatocellular carcinoma risk persists despite iron depletion
10-year survival decreases to 60-70% even with treatment³⁴
Liver transplantation may become necessary

This underscores the critical importance of early detection.

Quality of Life Outcomes

Iron depletion therapy consistently improves:

Fatigue (most dramatic improvement)
Hepatomegaly resolution
Cardiac function (if treated before severe cardiomyopathy)
Prevention of diabetes progression (though established diabetes rarely reverses)

Arthropathy notably does NOT improve with iron depletion—making it particularly important to diagnose before joint damage occurs.²¹

Controversies and Unresolved Questions

Population Screening: To Screen or Not to Screen?

Despite HH frequency and treatability, routine population screening remains controversial:

Arguments for screening:

High prevalence in at-risk populations
Simple, inexpensive testing
Highly effective, safe treatment
Prevention of irreversible complications

Arguments against:

Low clinical penetrance (90% of homozygotes never develop complications)
Risk of labeling and anxiety
Unclear cost-effectiveness given low penetrance
Potential for insurance discrimination (mitigated but not eliminated)

Current consensus (2024): Opportunistic screening of high-risk individuals rather than universal population screening.³⁵ Guidelines recommend testing patients with suggestive clinical features and cascade screening of family members.

The Ferritin Paradox: How Low Should We Go?

Target ferritin for maintenance therapy remains debated:

Some advocate 50-100 ng/mL (near-normal stores)
Others suggest <50 ng/mL for maximum benefit
Overly aggressive depletion (<20 ng/mL) causes iron deficiency, fatigue

Practical approach: Target 50-100 ng/mL initially; individualize based on symptom response and tolerance.

Conclusions and Key Takeaways

Hereditary hemochromatosis exemplifies precision medicine: a common genetic disorder with variable penetrance, straightforward diagnosis, and remarkably effective treatment—if recognized early. The tragedy lies in late diagnosis after irreversible complications develop.

Ten Commandments for the Practicing Internist:

Think of HH in patients with unexplained liver disease, diabetes, arthropathy (especially MCPs), or fatigue
Screen with fasting transferrin saturation and ferritin—TSAT is the best screening test
Confirm with HFE genetic testing when TSAT ≥45%
Remember that most C282Y homozygotes never develop severe disease—penetrance is low but unpredictable
Assess for end-organ damage before starting treatment
Treat with therapeutic phlebotomy—it works, it's cheap, it's safe
Target ferritin 50-100 ng/mL for maintenance therapy
Screen all first-degree relatives—this prevents future disease
Counsel about alcohol avoidance—synergistic hepatotoxicity
Reassure patients that early diagnosis means normal life expectancy

Hemochromatosis testing should be as reflexive as checking TSH in fatigue or HbA1c in polyuria. With vigilance, we can transform this "missed diagnosis" into a clinical success story—identifying and treating patients before they enter our offices with bronze skin, cirrhosis, and diabetes, instead catching them early when a simple blood draw prevents decades of suffering.

References

Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352(17):1769-1778.
European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010;53(1):3-22.
Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13(4):399-408.
Wahedi M, Worthington J, Enns CA, et al. The HFE protein: molecular basis and physiologic consequences. Hepatology. 2002;35(6):1477-1480.
Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(1):328-343.
Distante S, Robson KJ, Graham-Campbell J, et al. The origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet. 2004;115(4):269-279.
Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G→ A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002;359(9302):211-218.
Powell LW, Dixon JL, Ramm GA, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med. 2006;166(3):294-301.
Pietrangelo A. Non-HFE hemochromatosis. Hepatology. 2004;39(1):21-29.
Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358(3):221-230.
Phatak PD, Sham RL, Raubertas RF, et al. Prevalence of hereditary hemochromatosis in 16031 primary care patients. Ann Intern Med. 1998;129(11):954-961.
McLaren CE, Garner CP, Constantine CC, et al. Genome-wide association study identifies genetic loci associated with iron deficiency. PLoS One. 2011;6(3):e17390.
Fleming DJ, Tucker KL, Jacques PF, et al. Dietary factors associated with the risk of high iron stores in the elderly Framingham Heart Study cohort. Am J Clin Nutr. 2002;76(6):1375-1384.
Fletcher LM, Dixon JL, Purdie DM, et al. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology. 2002;122(2):281-289.
Bardou-Jacquet E, Ben Ali Z, Beaumont-Epinette MP, et al. Non-HFE hemochromatosis: pathophysiological and diagnostic aspects. Clin Res Hepatol Gastroenterol. 2014;38(2):143-154.
Ruddell RG, Nemeth E, Ramm GA. Iron metabolism, iron homeostasis and the inflammatory response. Clin Biochem Rev. 2008;29(2):47-62.
Niederau C, Fischer R, Purschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110(4):1107-1119.
Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet. 2016;388(10045):706-716.
Elmberg M, Hultcrantz R, Ekbom A, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology. 2003;125(6):1733-1741.
Simcox JA, McClain DA. Iron and diabetes risk. Cell Metab. 2013;17(3):329-341.
Carroll GJ, Breidahl WH, Bulsara MK, et al. Hereditary hemochromatosis is characterized by a clinically definable arthropathy that correlates with iron load. Arthritis Rheum. 2011;63(1):286-294.
Adams PC, Barton JC. How I treat hemochromatosis. Blood. 2010;116(3):317-325.
Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology. 1998;115(4):929-936.
Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171-2179.
Morrison ED, Brandhagen DJ, Phatak PD, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med. 2003;138(8):627-633.
Barton JC, McDonnell SM, Adams PC, et al. Management of hemochromatosis. Ann Intern Med. 1998;129(11):932-939.
Adams PC, Passmore L, Chakrabarti S, et al. Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol. 2006;4(7):918-923.
Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733-3737.
Åsberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol. 2001;36(10):1108-1115.
Hickman PE, Hourigan LF, Powell LW, et al. Automated analysis improves the ability of transferrin saturation to detect hemochromatosis. Clin Chem. 2009;55(9):1672-1679.
Kowdley KV, Belt P, Wilson LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55(1):77-85.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236.
Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985;313(20):1256-1262.
Fracanzani AL, Conte D, Fraquelli M, et al. Increased cancer risk in a coh

ort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology. 2001;33(3):647-651.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: HFE hemochromatosis. J Hepatol. 2022;77(2):479-502.

Author Declaration: The author declares no conflicts of interest related to this publication.

Word Count: 4,987 words (excluding references)